FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385816805> ?p ?o ?g. }

• W4385816805 abstract "Many advances in the understanding of the pathologic and molecular features of endometrial cancer have occurred since the FIGO staging was last updated in 2009. Substantially more outcome and biological behavior data are now available regarding the several histological types. Molecular and genetic findings have accelerated since the publication of The Cancer Genome Atlas (TCGA) data and provide improved clarity on the diverse biological nature of this collection of endometrial cancers and their differing prognostic outcomes. The goals of the new staging system are to better define these prognostic groups and create substages that indicate more appropriate surgical, radiation, and systemic therapies.The FIGO Women's Cancer Committee appointed a Subcommittee on Endometrial Cancer Staging in October 2021, represented by the authors. Since then, the committee members have met frequently and reviewed new and established evidence on the treatment, prognosis, and survival of endometrial cancer. Based on these data, opportunities for improvements in the categorization and stratification of these factors were identified in each of the four stages. Data and analyses from the molecular and histological classifications performed and published in the recently developed ESGO/ESTRO/ESP guidelines were used as a template for adding the new subclassifications to the proposed molecular and histological staging system.Based on the existing evidence, the substages were defined as follows: Stage I (IA1): non-aggressive histological type of endometrial carcinoma limited to a polyp or confined to the endometrium; (IA2) non-aggressive histological types of endometrium involving less than 50% of the myometrium with no or focal lymphovascular space invasion (LVSI) as defined by WHO criteria; (IA3) low-grade endometrioid carcinomas limited to the uterus with simultaneous low-grade endometrioid ovarian involvement; (IB) non-aggressive histological types involving 50% or more of the myometrium with no LVSI or focal LVSI; (IC) aggressive histological types, i.e. serous, high-grade endometrioid, clear cell, carcinosarcomas, undifferentiated, mixed, and other unusual types without any myometrial invasion. Stage II (IIA): non-aggressive histological types that infiltrate the cervical stroma; (IIB) non-aggressive histological types that have substantial LVSI; or (IIC) aggressive histological types with any myometrial invasion. Stage III (IIIA): differentiating between adnexal versus uterine serosa infiltration; (IIIB) infiltration of vagina/parametria and pelvic peritoneal metastasis; and (IIIC) refinements for lymph node metastasis to pelvic and para-aortic lymph nodes, including micrometastasis and macrometastasis. Stage IV (IVA): locally advanced disease infiltrating the bladder or rectal mucosa; (IVB) extrapelvic peritoneal metastasis; and (IVC) distant metastasis. The performance of complete molecular classification (POLEmut, MMRd, NSMP, p53abn) is encouraged in all endometrial cancers. If the molecular subtype is known, this is recorded in the FIGO stage by the addition of m for molecular classification, and a subscript indicating the specific molecular subtype. When molecular classification reveals p53abn or POLEmut status in Stages I and II, this results in upstaging or downstaging of the disease (IICmp53abn or IAmPOLEmut).The updated 2023 staging of endometrial cancer includes the various histological types, tumor patterns, and molecular classification to better reflect the improved understanding of the complex nature of the several types of endometrial carcinoma and their underlying biologic behavior. The changes incorporated in the 2023 staging system should provide a more evidence-based context for treatment recommendations and for the more refined future collection of outcome and survival data." @default.
• W4385816805 created "2023-08-15" @default.
• W4385816805 creator A5006958187 @default.
• W4385816805 creator A5025519748 @default.
• W4385816805 creator A5029407696 @default.
• W4385816805 creator A5031844208 @default.
• W4385816805 creator A5057224046 @default.
• W4385816805 creator A5067980172 @default.
• W4385816805 creator A5069925431 @default.
• W4385816805 creator A5075073315 @default.
• W4385816805 creator A5076087889 @default.
• W4385816805 date "2023-01-01" @default.
• W4385816805 modified "2023-10-14" @default.
• W4385816805 title "FIGO staging of endometrial cancer: 2023" @default.
• W4385816805 cites W1555947040 @default.
• W4385816805 cites W1565078991 @default.
• W4385816805 cites W1903539786 @default.
• W4385816805 cites W1974476536 @default.
• W4385816805 cites W1975737078 @default.
• W4385816805 cites W1978544119 @default.
• W4385816805 cites W1978834148 @default.
• W4385816805 cites W1983517524 @default.
• W4385816805 cites W2007160797 @default.
• W4385816805 cites W2007269627 @default.
• W4385816805 cites W2014992164 @default.
• W4385816805 cites W2031222466 @default.
• W4385816805 cites W2039677409 @default.
• W4385816805 cites W2041440766 @default.
• W4385816805 cites W2072392962 @default.
• W4385816805 cites W2081494331 @default.
• W4385816805 cites W2085953226 @default.
• W4385816805 cites W2091713419 @default.
• W4385816805 cites W2094092471 @default.
• W4385816805 cites W2110037976 @default.
• W4385816805 cites W2168808178 @default.
• W4385816805 cites W2182443159 @default.
• W4385816805 cites W2207865108 @default.
• W4385816805 cites W2222410622 @default.
• W4385816805 cites W2270264837 @default.
• W4385816805 cites W2277875883 @default.
• W4385816805 cites W2303306419 @default.
• W4385816805 cites W2318235703 @default.
• W4385816805 cites W2318473267 @default.
• W4385816805 cites W2323563331 @default.
• W4385816805 cites W2326465893 @default.
• W4385816805 cites W2337786508 @default.
• W4385816805 cites W2566465729 @default.
• W4385816805 cites W2570729870 @default.
• W4385816805 cites W2573152477 @default.
• W4385816805 cites W2620765662 @default.
• W4385816805 cites W2622499649 @default.
• W4385816805 cites W2734610904 @default.
• W4385816805 cites W2756514692 @default.
• W4385816805 cites W2762665899 @default.
• W4385816805 cites W2789454469 @default.
• W4385816805 cites W2793947731 @default.
• W4385816805 cites W2794053055 @default.
• W4385816805 cites W2892025730 @default.
• W4385816805 cites W2900333014 @default.
• W4385816805 cites W2903576199 @default.
• W4385816805 cites W2904103532 @default.
• W4385816805 cites W2908657103 @default.
• W4385816805 cites W2920500891 @default.
• W4385816805 cites W2920721871 @default.
• W4385816805 cites W2944612317 @default.
• W4385816805 cites W2946550609 @default.
• W4385816805 cites W2948493809 @default.
• W4385816805 cites W2963015093 @default.
• W4385816805 cites W2966822422 @default.
• W4385816805 cites W2972464382 @default.
• W4385816805 cites W2994917102 @default.
• W4385816805 cites W2994973919 @default.
• W4385816805 cites W2996314623 @default.
• W4385816805 cites W3014386794 @default.
• W4385816805 cites W3022521805 @default.
• W4385816805 cites W3043785960 @default.
• W4385816805 cites W3044249289 @default.
• W4385816805 cites W3047152751 @default.
• W4385816805 cites W3114074286 @default.
• W4385816805 cites W3121667659 @default.
• W4385816805 cites W3122480463 @default.
• W4385816805 cites W3131758164 @default.
• W4385816805 cites W3134365863 @default.
• W4385816805 cites W313450500 @default.
• W4385816805 cites W3181471292 @default.
• W4385816805 cites W3193307874 @default.
• W4385816805 cites W3197760084 @default.
• W4385816805 cites W4224982859 @default.
• W4385816805 cites W4283373318 @default.
• W4385816805 cites W4317718278 @default.
• W4385816805 cites W4360991857 @default.
• W4385816805 cites W4360992337 @default.
• W4385816805 cites W4376253741 @default.
• W4385816805 doi "https://doi.org/10.3802/jgo.2023.34.e85" @default.
• W4385816805 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37593813" @default.
• W4385816805 hasPublicationYear "2023" @default.
• W4385816805 type Work @default.
• W4385816805 citedByCount "1" @default.
• W4385816805 crossrefType "journal-article" @default.
• W4385816805 hasAuthorship W4385816805A5006958187 @default.

• next